Here's the concrete reader question: when a company is riding the biggest drug launch in a generation, what does it tell its own shareholders about the risks? The answer is in the filing, not the press release. Eli Lilly's annual report on Form 10-K, filed February 12, 2026, is where the company has to be honest under penalty of securities law — and on the incretin franchise it is notably measured.
Strip away the press release and you find Lilly tying future performance to the demand and pace of uptake in new incretin channels and markets for Zepbound and, if approved, the oral incretin orforglipron. That single phrase carries a lot: it concedes that the franchise's trajectory is not locked in, that it depends on getting more patients onto the drugs, and that an oral version is a bet still awaiting approval. This is the company telling you where its own growth assumptions live.
The supply story is the other half. Lilly's recent filings have repeatedly disclosed that demand for its incretin medicines exceeded what it could make. The 2025 10-K stated that during 2024 demand for its incretin medicines exceeded supply, and the 2024 10-K warned that tight supplies of incretin products would persist while additional manufacturing came online. The 2023 10-K framed the same period around challenges in meeting demand. Read in sequence, these filings document a multi-year capacity scramble.
Why does this matter to a general reader? Because a supply-constrained blockbuster behaves differently from a demand-constrained one. When you cannot make enough, every quarter's revenue is partly a manufacturing number, and the competitive threat is less about whether patients want the drug and more about whether someone else can fill the gap. The filing's careful wording is the company managing exactly that tension on the record.
The EdgarBeast evidence index, which surfaces and normalizes SEC filings, makes it possible to line up four consecutive Lilly annual reports and watch the language evolve from challenges in meeting demand to descriptions of new channels and an oral follow-on. That progression is the real story: a franchise moving from can we make it toward can we keep growing it.
None of this is a verdict on the stock — biotechdocket does not make those calls. It is a reading of what the primary document discloses. And what it discloses is that even the most celebrated drug franchise in biotech is described, by its own maker, as a set of risks to be managed: uptake, channels, an unapproved oral, and the long shadow of supply.